I just posted my summary of the Celgene analyst call and results for Q4 2011.
Celgene just acquired Abraxis and has a large number of clinical trials underway. It looks to me like it could double its revenues again by 2015. Great for a long-term investor, but there is always the risk that drug candidates will fail to be approved.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment